Sponsors

Micafungin added to fungal susceptibility card

bioMérieux has created a new fungal susceptibility card for susceptibility testing of Candida species and Cryptococcus neoformans. The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations. Early diagnosis and prompt treatment are key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardised and rapid yeast susceptibility
testing.

The VITEK 2 AST-YS07 fungal susceptibility card, which replaces VITEK 2 AST-YS06, complements the current antifungals – amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole – with micafungin, an echinocandin active against Candida species, extending the capabilities of the
VITEK 2 and helping to ensure that the correct treatment is initiated swiftly.
www.biomerieux.com

Latest Issues

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Ghent Pathology 2025

ICC Ghent, Belgium
24-26 June, 2025